These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 9300578)

  • 1. Effects of olomoucine, a selective inhibitor of cyclin-dependent kinases, on cell cycle progression in human cancer cell lines.
    Buquet-Fagot C; Lallemand F; Montagne MN; Mester J
    Anticancer Drugs; 1997 Jul; 8(6):623-31. PubMed ID: 9300578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases.
    Abraham RT; Acquarone M; Andersen A; Asensi A; Bellé R; Berger F; Bergounioux C; Brunn G; Buquet-Fagot C; Fagot D
    Biol Cell; 1995; 83(2-3):105-20. PubMed ID: 7549905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity.
    Alessi F; Quarta S; Savio M; Riva F; Rossi L; Stivala LA; Scovassi AI; Meijer L; Prosperi E
    Exp Cell Res; 1998 Nov; 245(1):8-18. PubMed ID: 9828096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells.
    Iseki H; Ko TC; Xue XY; Seapan A; Hellmich MR; Townsend CM
    Surgery; 1997 Aug; 122(2):187-94; discussion 194-5. PubMed ID: 9288122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERK pathway mediates the activation of Cdk2 in IGF-1-induced proliferation of human osteosarcoma MG-63 cells.
    Zhang W; Lee JC; Kumar S; Gowen M
    J Bone Miner Res; 1999 Apr; 14(4):528-35. PubMed ID: 10234573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics.
    Schutte B; Nieland L; van Engeland M; Henfling ME; Meijer L; Ramaekers FC
    Exp Cell Res; 1997 Oct; 236(1):4-15. PubMed ID: 9344580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin-dependent kinase inhibitors.
    Legraverend M; Ludwig O; Bisagni E; Leclerc S; Meijer L; Giocanti N; Sadri R; Favaudon V
    Bioorg Med Chem; 1999 Jul; 7(7):1281-93. PubMed ID: 10465404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
    Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
    Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel strategy for inhibiting growth of human pancreatic cancer cells by blocking cyclin-dependent kinase activity.
    Iseki H; Ko TC; Xue XY; Seapan A; Townsend CM
    J Gastrointest Surg; 1998; 2(1):36-43. PubMed ID: 9841966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular effects of olomoucine in human lymphoma cells differing in p53 function.
    Fan S; Duba DE; O'Connor PM
    Chemotherapy; 1999; 45(6):437-45. PubMed ID: 10567774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenovirus-mediated E2F-1 gene transfer induces an apoptotic response in human gastric carcinoma cells that is enhanced by cyclin dependent kinase inhibitors.
    Atienza C; Elliott MJ; Dong YB; Yang HL; Stilwell A; Liu TJ; McMasters KM
    Int J Mol Med; 2000 Jul; 6(1):55-63. PubMed ID: 10851267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olomoucine, an inhibitor of the cdc2/cdk2 kinases activity, blocks plant cells at the G1 to S and G2 to M cell cycle transitions.
    Glab N; Labidi B; Qin LX; Trehin C; Bergounioux C; Meijer L
    FEBS Lett; 1994 Oct; 353(2):207-11. PubMed ID: 7523194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caspase-mediated Cdk2 activation is a critical step to execute transforming growth factor-beta1-induced apoptosis in human gastric cancer cells.
    Kim SG; Kim SN; Jong HS; Kim NK; Hong SH; Kim SJ; Bang YJ
    Oncogene; 2001 Mar; 20(10):1254-65. PubMed ID: 11313870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early inhibition of DNA synthesis in the developing rat cerebral cortex by the purine analogues olomoucine and roscovitine.
    Yakisich JS; Sidén A; Idoyaga Vargas V; Eneroth P; Cruz M
    Biochem Biophys Res Commun; 1998 Feb; 243(3):674-7. PubMed ID: 9500988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Helicobacter pylori releases a factor(s) inhibiting cell cycle progression of human gastric cell lines by affecting cyclin E/cdk2 kinase activity and Rb protein phosphorylation through enhanced p27(KIP1) protein expression.
    Sommi P; Savio M; Stivala LA; Scotti C; Mignosi P; Prosperi E; Vannini V; Solcia E
    Exp Cell Res; 2002 Nov; 281(1):128-39. PubMed ID: 12441136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cyclin-dependent kinase inhibitor, butyrolactone I, inhibits phosphorylation of RB protein and cell cycle progression.
    Kitagawa M; Higashi H; Takahashi IS; Okabe T; Ogino H; Taya Y; Hishimura S; Okuyama A
    Oncogene; 1994 Sep; 9(9):2549-57. PubMed ID: 8058318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells.
    David-Pfeuty T
    Oncogene; 1999 Dec; 18(52):7409-22. PubMed ID: 10602500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiproliferative effect of plant cytokinin analogues with an inhibitory activity on cyclin-dependent kinases.
    Vermeulen K; Strnad M; Krystof V; Havlícek L; Van der Aa A; Lenjou M; Nijs G; Rodrigus I; Stockman B; van Onckelen H; Van Bockstaele DR; Berneman ZN
    Leukemia; 2002 Mar; 16(3):299-305. PubMed ID: 11896531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor Tomudex.
    Yin MB; Guo B; Panadero A; Frank C; Wrzosek C; Slocum HK; Rustum YM
    Exp Cell Res; 1999 Feb; 247(1):189-99. PubMed ID: 10047461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.
    Raynaud FI; Whittaker SR; Fischer PM; McClue S; Walton MI; Barrie SE; Garrett MD; Rogers P; Clarke SJ; Kelland LR; Valenti M; Brunton L; Eccles S; Lane DP; Workman P
    Clin Cancer Res; 2005 Jul; 11(13):4875-87. PubMed ID: 16000586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.